<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04087863</url>
  </required_header>
  <id_info>
    <org_study_id>K0103</org_study_id>
    <nct_id>NCT04087863</nct_id>
  </id_info>
  <brief_title>Administration for Placebo Group and Evalution the Safety and Efficacy in Atopic Dermatitis Patients</brief_title>
  <official_title>A Multi-center, Open, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis Who Participated in a Placebo Group in K0102 Clinical Trial: 2nd Extension Study of K0102</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kang Stem Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kang Stem Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-center, Open, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of
      FURESTEM-AD inj. in Patients with Moderate to Severe Chronic Atopic Dermatitis Who
      Participated in a Placebo Group in K0102 Clinical Trial: 2nd Extension Study of K0102
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment (Rate of Adverse Event, Number of Participants with Adverse Event)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose Eczema Area and Severity Index (EASI) was decreased from baseline by more than 75% at each visit (EASI-75)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose Eczema Area and Severity Index (EASI) was decreased from baseline by more than 50% at each visit (EASI-50)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in EASI from baseline</measure>
    <time_frame>3 years</time_frame>
    <description>EASI range is from 0 (clear) to 72 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EASI from baseline</measure>
    <time_frame>3 years</time_frame>
    <description>EASI range is from 0 (clear) to 72 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose Investigator's Global Assessment (IGA) score at each visit is 0 or 1</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose IGA at each visit is 0 or 1, or improved to 2 or higher</measure>
    <time_frame>3 years</time_frame>
    <description>IGA score is from 0 (clear) to 5 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose SCORing Atopic Dermatitis (SCORAD) INDEX was decreased from baseline by more than 50% at each visit (SCORAD-50)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in SCORAD index from baseline at each visit</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SCORAD index from baseline at each visit</measure>
    <time_frame>3 years</time_frame>
    <description>SCORAD index range is from 0 (clear) to 103 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in Extent, Intensity of lesions and subject symptoms for SCORAD index from baseline at each visit</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Extent, Intensity of lesions and subject symptoms for SCORAD index from baseline at each visit</measure>
    <time_frame>3 years</time_frame>
    <description>SCORAD index range is from 0 (clear) to 103 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total serum Immunoglobulin E(IgE) from baseline</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in total serum Immunoglobulin E(IgE) from baseline</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Atopic Dermatitis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not applicable(observational study)</intervention_name>
    <description>Not applicable(observational study)</description>
    <arm_group_label>Atopic Dermatitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Moderate to Severe Atopic Dermatitis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject who enrolled K0102 Clinical Trial(parent study) and be assigned to a placebo
             group

          2. Subjects who understand and voluntarily sign an informed consent form

        Exclusion Criteria:

          1. Subjects with medical history or surgery/procedure history

          2. Subjects with diseases at the time of participation in this study (systemic infection,
             other serious skin disorders, pigmentation or extensive scarring in atopic dermatitis
             symptom region)

          3. Pregnant, breast-feeding women or women who plan to become pregnant during six months
             after administering the clinical trial medication

          4. Subjects who participate in other clinical trial or participated in other clinical
             trial within 4 weeks

          5. In case follow-up is not possible to end of this study period

          6. Any other condition which the investigator judges would make patient unsuitable for
             study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seulbi Lee</last_name>
    <phone>+82-2-888-1592</phone>
    <email>sblee@kangstem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong-hyang Woo</last_name>
    <phone>+82-2-888-1592</phone>
    <email>jhwoo@kangstem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sukyung Park</last_name>
      <phone>+82-2-2258-8196</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

